Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Merck's shares have lost 15.3% in the past year compared with a decline of 3.9% for the industry. Merck MRK stock has declined 8.8% in the past three months.

In this note, while we briefly touch upon Merck’s performance in 2024, we focus on the impact on MRK stock and how 2025 could turn out. But, if you want upside with a smoother ride than an ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck's strong performance in the past two years has outperformed the market. Find out why I recommend a Buy rating for MRK stock at its current price.